GEN Exclusives

More »

GEN News Highlights

More »
Jan 29, 2008

Cryo-Cell and Saneron Sign Neurodegenerative Disorder Deal Using Stem Cell Technology

  • Cryo-Cell inked an R&D agreement with Saneron CCEL Therapeutics to develop regenerative therapies using Cryo-Cell’s C’elle menstrual stem cell technology. The partners will work on preclinical models for particular neurological diseases.

    Cryo-Cell will provide C’elle menstrual stem cells along with associated techniques. Saneron will contribute study materials and research methodology for potential therapeutic applications. The companies will jointly own any intellectual property resulting from this research.

    Cryo-Cell and Saneron will, according Julie Allickson, Ph.D., Cryo-Cell’s vp of laboratory operations and R&D, “explore utilization of C’elle menstrual stem cells in the development of potential breakthrough therapies for three very devastating disorders.”

    C’elle stem cells, derived from menstrual flow, contains millions of stem cells that have many properties and characteristics similar to those of both bone marrow and embryonic stem cells, according to the firms.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »